Literature DB >> 10916176

Freedman's 'clinical equipoise' and sliding-scale all-dimensions-considered equipoise'.

F Gifford1.   

Abstract

It is often claimed that a clinical investigator may ethically participate (e.g., enroll patients) in a trial only if she is in equipoise (if she has no way to ground a preference for one arm of the study). But this is a serious problem, for as data accumulate, it can be expected that there will be a discernible trend favoring one of the treatments prior to the point where we achieve the trial's objective. In this paper, I critically evaluate Benjamin Freedman's 'clinical equipoise' solution to this dilemma. I argue that Freedman actually puts forth at least two distinct contrasts--one in terms of community vs. individual equipoise, and another concerning clinical vs. theoretical equipoise--and that neither of them resolves the dilemma. I then make a proposal for a more adequate account of how to think about the circumstances under which entering subjects in trials would be justified--a 'sliding-scale equipoise' that arises out of a discussion of patients' values.

Entities:  

Mesh:

Year:  2000        PMID: 10916176     DOI: 10.1076/0360-5310(200008)25:4;1-A;FT399

Source DB:  PubMed          Journal:  J Med Philos        ISSN: 0360-5310


  5 in total

1.  Uncertainty about clinical equipoise. Clinical equipoise and the uncertainty principles both require further scrutiny.

Authors:  F Gifford
Journal:  BMJ       Date:  2001-03-31

Review 2.  Use and abuse of empirical knowledge in contemporary bioethics.

Authors:  Jan Helge Solbakk
Journal:  Med Health Care Philos       Date:  2004

Review 3.  Should desperate volunteers be included in randomised controlled trials?

Authors:  P Allmark; S Mason
Journal:  J Med Ethics       Date:  2006-09       Impact factor: 2.903

4.  Uncertainty and the ethics of clinical trials.

Authors:  Sven Ove Hansson
Journal:  Theor Med Bioeth       Date:  2006

5.  Ethics of randomised controlled trials--not yet time to give up on equipoise.

Authors:  Richard E Ashcroft
Journal:  Arthritis Res Ther       Date:  2004-09-14       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.